Prognostic factors selected for time to metastases and DSS by multivariate Cox regression
| Factor . | Time to metastases . | . | DSS . | . | ||||
|---|---|---|---|---|---|---|---|---|
| . | Hazard ratio (95% CI) . | P . | Hazard ratio (95% CI) . | P . | ||||
| Model A with PCR as combined variable (n = 105) | ||||||||
| PCR* | 7.3 (2.9-18) | <0.001 | 22.6 (6.9-74) | <0.001 | ||||
| Largest tumor diameter | 2.6 (1.04-6.5) | 0.041 | 4.7 (1.3-17) | 0.020 | ||||
| Karnofsky performance status | 6.0 (1.2-30) | 0.029 | ||||||
| Age† | 1.03 (0.9-1.1) | 0.081 | ||||||
| Model B with tyrosinase and MelanA/MART1 as separate variables (n = 95) | ||||||||
| Tyrosinase | 5.3 (1.7-17) | 0.005 | 5.1 (1.2-21) | 0.024 | ||||
| MelanA/MART1 | 9.9 (2.9-34) | <0.001 | 35.9 (5.5-198) | <0.001 | ||||
| Largest tumor diameter | 3.8 (1.2-12) | 0.019 | 10.0 (1.6-63) | 0.014 | ||||
| Karnofsky performance status | 6.7 (1.3-33) | 0.021 | ||||||
| Model C with PCR as combined variable (n = 75) | ||||||||
| PCR* | 14.6 (3-70) | 0.001 | 134.0 (9-1,999) | <0.001 | ||||
| Largest tumor diameter | 6.2 (1.2-34) | 0.033 | 8.1 (0.8-79) | 0.072 | ||||
| Karnofsky performance status | 25.0 (1.6-333) | 0.022 | ||||||
| Sex‡ | 6.7 (0.7-50) | 0.082 | ||||||
| Factor . | Time to metastases . | . | DSS . | . | ||||
|---|---|---|---|---|---|---|---|---|
| . | Hazard ratio (95% CI) . | P . | Hazard ratio (95% CI) . | P . | ||||
| Model A with PCR as combined variable (n = 105) | ||||||||
| PCR* | 7.3 (2.9-18) | <0.001 | 22.6 (6.9-74) | <0.001 | ||||
| Largest tumor diameter | 2.6 (1.04-6.5) | 0.041 | 4.7 (1.3-17) | 0.020 | ||||
| Karnofsky performance status | 6.0 (1.2-30) | 0.029 | ||||||
| Age† | 1.03 (0.9-1.1) | 0.081 | ||||||
| Model B with tyrosinase and MelanA/MART1 as separate variables (n = 95) | ||||||||
| Tyrosinase | 5.3 (1.7-17) | 0.005 | 5.1 (1.2-21) | 0.024 | ||||
| MelanA/MART1 | 9.9 (2.9-34) | <0.001 | 35.9 (5.5-198) | <0.001 | ||||
| Largest tumor diameter | 3.8 (1.2-12) | 0.019 | 10.0 (1.6-63) | 0.014 | ||||
| Karnofsky performance status | 6.7 (1.3-33) | 0.021 | ||||||
| Model C with PCR as combined variable (n = 75) | ||||||||
| PCR* | 14.6 (3-70) | 0.001 | 134.0 (9-1,999) | <0.001 | ||||
| Largest tumor diameter | 6.2 (1.2-34) | 0.033 | 8.1 (0.8-79) | 0.072 | ||||
| Karnofsky performance status | 25.0 (1.6-333) | 0.022 | ||||||
| Sex‡ | 6.7 (0.7-50) | 0.082 | ||||||
NOTE: Covariates included into the analysis are age, sex, Karnofsky performance status, largest tumor diameter, extraocular growth, ciliary body infiltration, PCR, tyrosinase, MelanA/MART1, and time from diagnosis to blood sampling. (A) Model with PCR as combined variable, all patients. (B) Model with tyrosinase and MelanA/MART1 as separate variables, all patients. (C) Model with PCR as combined variable, subgroup of patients with blood sampling at primary local therapy. Forward and backward elimination gave identical results for time to metastases in all models and for DSS in model (B).
Tyrosinase or MelanA/MART1.
For disease-specific survival results of backward elimination are shown, in forward elimination age was not in the model.
For disease-specific survival, results of backward elimination are shown, in forward elimination sex was not in the model.